Exploratory data presented for Active Biotech's ANYARA project
(Thomson Reuters ONE) - Lund, Sweden, February 10, 2010 - Active Biotech AB (NASDAQ OMX Nordic:ACTI) haspresented results from exploratory preclinical studies at the Keystone Symposia"Molecular and Cellular Biology of Immune Escape in Cancer" held in Keystone,Colorado, USA, February 7-12.The complete poster "Combining tumor-targeted superantigens with anti-CTLA-4results in synergistic anti-tumor effects in B16 tumor bearing mice" can beviewed at www.activebiotech.com . The results ofthe study demonstrate that TTS therapy can be further enhanced by specificallymodulating the immune response in this experimental model.The drug candidate ANYARA, using the TTS technology, is currently in pivotalPhase III clinical trials for Renal Cell Cancer. The primary endpoint is overallsurvival and results from these studies are expected first half of 2011.Lund February 10, 2010Active Biotech AB (publ)Tomas LeandersonPresident and CEOFor further information, please contactG? ForsbergVP Investor Relations & Business DevelopmentTel: +46 (0)46 19 11 54goran.forsberg(at)activebiotech.com Notes to editorsAbout ANYARAANYARA is a TTS (Tumor TargetingSuperantigens) compound that makes the treatment of cancer tumor-specific. Thedevelopment of ANYARA is mainly focused on renal cell cancer. Positive data was reported inconnection with the interim analysis in Phase II/IIIandfrom clinical Phase I trials in lung cancer, renal cell cancer and pancreaticcancer. The median survival of 26.2 months observed for patients with advancedrenal cancer and treated with ANYARA is twice the expected length. ANYARA hasbeen granted orphan-drug status bythe EMEA for the indication renal cancer. Information concerning the ongoingPhase III clinical trial is available at www.activebiotech.com and www.clinicaltrials.gov.About Active BiotechActive Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company withfocus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phaseare laquinimod, an orally administered small molecule with uniqueimmunomodulatory properties for the treatment of multiple sclerosis, as well asANYARA for use in cancer targeted therapy, primarily of renal cancer. Furtherkey projects in clinical development comprise the three orally administeredcompounds TASQ for prostate cancer, 57-57 for SLE and RhuDex(TM) for RA. Pleasevisit www.activebiotech.com for moreinformation.Active Biotech ABPO Box 724, SE-220 07 LundSwedenTel: +46 (0)46-19 20 00Fax: +46 (0)46-19 11 00Active Biotech is required under the Securities Markets Act to make theinformation in this press release public. The information was submitted forpublication at 08:30 am CET on February 10, 2010.[HUG#1382236] Exploratory data presented for Active Biotech?s ANYARA project: http://hugin.info/1002/R/1382236/341185.pdf
Weitere Infos zu dieser Pressemeldung:Unternehmensinformation / Kurzprofil:Bereitgestellt von Benutzer: hugin
Datum: 10.02.2010 - 08:31 Uhr
Sprache: Deutsch
News-ID 12270
Anzahl Zeichen: 0
contact information:
Town:
Kategorie:
Diese Pressemitteilung wurde bisher
231 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"
Exploratory data presented for Active Biotech's ANYARA project"
steht unter der journalistisch-redaktionellen Verantwortung von
Active Biotech
(
Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum
Haftungsauschluß (gemäß
TMG - TeleMedianGesetz) und dem
Datenschutz (gemäß der
DSGVO).
Lund, Sweden, December 14, 2009 - A first analysis of the primary
endpoint based on data from at least six months' treatment of more
than 200 patients, has been performed in Active Biotech AB's (NASDAQ
OMX Nordic: ACTI) ongoing Phase II cli ...
In accordance with a decision made by the Annual General Meeting held
on May 7, 2009, the Election Committee shall comprise the
representatives for the three largest shareholders on September 30
and the Board Chairman.
For the 2010 Annual General ...
* Laquinimod -- new data presented at ECTRIMS
* 57-57 -- exploratory clinical trial in progress
* RhuDex(TM) -- clinical development to continue following feedback
from UK MHRA
* ANYARA -- complete Phase I data published
* TASQ -- complete Phase I ...
" alt="Osisko and Clifton Star Report 2009 Drill Results From the Duparquet Project
